Glaukos Highlights Three Year Epioxa Trial Results
Glaukos announced that patients treated with its Epioxa therapy for keratoconus maintained significant vision and corneal improvements three years after a single dose. The trial showed no serious adverse events and no need for additional medical interventions during the follow-up period.
Insights:
Glaukos said patients treated with its keratoconus therapy maintained vision improvements three years after a single dose. Epioxa eliminated the need for additional interventions during the study period. The data strengthens the medtech firm's regulatory and commercial positioning.
